Zanidatamab (ZW25) is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to significant anti-tumour activity in preclinical models of breast and gastric cancers.
Zanidatamab Clinical Trials
Zanidatamab is being evaluated in Phase 1 trials by Zymeworks as a potential treatment option for patients with HER2-expressing cancers.
For more clinical trial information, please visit CLINICALTRIALS.GOV.
Mechanisms of Action
Zanidatamab can potentially mediate its therapeutic effect on HER2-expressing tumours by the biparatopic targeting of HER2 resulting in:
- Increased maximum binding density and potent effector function-mediated cytotoxicity
- Cross-linked trans HER2 binding and HER2 receptor clustering
- Enhanced antibody internalization and HER2 downregulation
- Enhanced blockade of ligand-dependent and ligand-independent tumour growth